SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently the center of intense speculation as the community tracks ongoing acquisition negotiations with a group including Stripe and Advent International. Traders are actively debating potential buyout valuations above recent bids, driving significant volatility and volume in both shares and options as market participants position for a formal deal announcement.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance is trending as investors react to strong earnings and a surge in institutional ownership, with the community actively speculating on a potential short squeeze as momentum builds. Discussions are heavily focused on the company's long-term commercial trajectory, the significance of upcoming lung cancer trial data, and whether the stock's recent price action signals a broader re-rating.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is currently trending as investors debate its long-term valuation and AI growth potential, with community discussion sharply divided between those viewing recent price dips as a buying opportunity and others expressing concern over high P/E ratios and potential semiconductor sector saturation. Sentiment is further fueled by ongoing technical analysis of its support levels, reactions to broader chip sector financing narratives, and active monitoring of institutional activity ahead of upcoming earnings.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as investors weigh strong AI-driven revenue growth and aggressive regional infrastructure expansion against concerns regarding convertible debt and historical dilution. The community is focused on the upcoming earnings report, with many looking for a potential short squeeze fueled by significant short interest and anticipation that strong numbers will trigger a major revaluation.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

Netlist is trending as a major breakout play driven by the recent landmark settlement with Samsung and a new ITC patent infringement complaint against Micron, fueling widespread community discussion about a potential short squeeze. Investors are increasingly optimistic about the company's valuation, citing a growing backlog of pending licensing agreements and a broader momentum shift in the semiconductor memory sector.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

The IWM is trending as investors debate whether the ETF is reaching overextended levels at all-time highs or if small-cap momentum remains sustainable amid broader market rotations. Traders are actively monitoring potential resistance at recent highs while reacting to conflicting sentiment regarding interest rate policies and institutional positioning.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is facing intense community debate and volatility as its price drops below the psychological one-dollar threshold, with investors split between buying the dip and fearing a continued slide. The conversation is heavily focused on uncertainty regarding upcoming regulatory clarity and skepticism over institutional adoption.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines ($UMAC) is seeing heightened volatility and investor interest driven by a significant defense policy catalyst regarding new government tariffs on foreign-made drones, which is expected to favor domestic manufacturers. The community is heavily focused on the stock's short-squeeze potential and potential for long-term domestic supply chain growth, though some participants remain cautious due to ongoing share dilution concerns and the stock's high sensitivity to speculative news flow.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is seeing increased volatility as investors weigh the company's long-term potential against concerns over the expiration of government reimbursements and the need for greater clarity on revenue guidance. While the community remains divided over management's communication and recent leadership changes, many are actively monitoring for updates on product adoption, institutional ownership trends, and the status of ongoing clinical milestones.

EyePoint, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

EyePoint Inc.

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals is seeing heavy trading activity as investors monitor the upcoming Phase 3 trial readouts for DURAVYU, with community sentiment split between excitement over potential durability advantages and caution regarding short interest and pending binary trial catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IONS Investors Have Opportunity to Join Ionis Pharmaceuticals, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. (Ionis or the Company) (NASDAQ: IONS) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026...

Monday 8/3 Insider Buying Report: IONS, VFC

As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys.

On Friday, Ionis Pharmaceuticals' Director, Michael R. Hayden, made a $1.06M buy of...

IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook

Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026...

Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised

Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +51.69% and +40.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Ionis announces Dr. Frank Bennett, chief scientific officer, to retire

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027.As a founding scientist, Frank has been instrumental in shaping Ionis and advancing the entire field of RNA-targeted...

Ionis reports second quarter 2026 financial results and highlights progress on key programs

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the Company) today reported financial results and provided key updates for the second quarter ended June 30, 2026. With the approval of TRYNGOLZA in late June, Ionis is bringing the first and only treatment to reduce triglycerides and acute pancreatitis...

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS PR Newswire SAN FRANCISCO, July 23, 2026 SAN FRANCISCO, July 23...

$IONS Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.69 down -188.46% YoY
• Reported revenue of $268M down -40.71% YoY
• Ionis Pharmaceuticals remains on track to achieve its 2026 financial guidance, including full-year product sales targets for TRYNGOLZA and DAWNZERA, while maintaining its goal of cashflow breakeven in 2028.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.

Ionis Pharmaceuticals Inc

BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’

Equity

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

IONSIonis Pharmaceuticals Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest IONS News